mulary deletions, restrictions, etc., must also be submitted on this form. Updates to the National Formulary will be published regularly following National P&T review. Comments and suggestions should be directed to the BOP Chief Pharmacist. Unless indicated as a non-substitutable product (i.e. negative formulary